公开(公告)号：US20220395512A1

公开(公告)日：2022-12-15

申请号：US17663716

申请日：2022-05-17

申请人： TMEM16A Limited

发明人： Stephen Collingwood ,  Clive Mccarthy ,  Jonathan David Hargrave ,  Duncan Alexander Hay ,  Thomas Beauregard Schofield ,  Sarah Ellam ,  Craig Stephen Buxton ,  Matthew Habgood ,  Peter Neville Ingram ,  Chun Yan Ma ,  Spencer Charles Robert Napier ,  Abdul Kadar Shaikh ,  Matthew Raymond Smith ,  Christopher Charles Stimson ,  Edward Richard Walker

IPC分类号： A61K31/5377 ,  A61K31/167 ,  A61K31/351 ,  A61K31/4025 ,  A61K31/4045 ,  A61K31/416 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/498 ,  A61K45/06 ,  C07C233/76 ,  C07D209/18 ,  C07D213/81 ,  C07D231/56 ,  C07D309/14 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12

摘要： Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.

公开(公告)号：US11364246B2

公开(公告)日：2022-06-21

申请号：US16501493

申请日：2019-11-22

申请人： TMEM16A Limited

发明人： Stephen Collingwood ,  Clive Mccarthy ,  Jonathan David Hargrave ,  Duncan Alexander Hay ,  Thomas Beauregard Schofield ,  Sarah Ellam ,  Craig Stephen Buxton ,  Matthew Habgood ,  Peter Neville Ingram ,  Chun Yan Ma ,  Spencer Charles Robert Napier ,  Abdul Kadar Shaikh ,  Matthew Raymond Smith ,  Christopher Charles Stimson ,  Edward Richard Walker

IPC分类号： C07D413/12 ,  A61K31/5377 ,  A61K31/167 ,  A61K31/351 ,  A61K31/4025 ,  A61K31/4045 ,  A61K31/416 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/498 ,  A61K45/06 ,  C07C233/76 ,  C07D209/18 ,  C07D213/81 ,  C07D231/56 ,  C07D309/14 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12

摘要： Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.